OBJECTIVE: To observe the impact of intraoperative peritoneal chemotherapy with @entity13750 on the safety of postoperative bowel function and complications in @entity1 with advanced @entity14 . METHODS: A total of 103 @entity14 @entity1 undergoing surgical operations in our department between October 2013 and October 2014 were prospectively enrolled in this study and were randomly divided into peritoneal chemotherapy group(55 cases) and control group(48 cases) according to the random table. In therapy group, @entity1 were treated with peritoneal implantation of 40 mg @entity13750 intraoperatively and followed by intravenous chemotherapy using FOLFOX regimen with @entity901 , @entity1487 and @entity4181 . In control group, only FOLFOX regimen was fulfilled. Then the recovery time of bowel function, the incidence of adverse reactions and complications, and the pre- and post-chemotherapy routine blood tests and hepatorenal functions were compared. RESULTS: The recovery time of bowel function in peritoneal chemotherapy group and control group was(72.1  11.8) h and(68.7  13.4) h respectively without significant difference(P>0.05). Each group had 6 cases with incisional fat liquefaction(10.9% vs. 12.5%, P>0.05). There was no serious @entity281 in both groups. During intravenous chemotherapy, in peritoneal chemotherapy group and control group, the incidence of @entity390 and vomit(42 cases, 76.4% vs. 40 cases, 83.3%), @entity1142 (38 cases, 69.1% vs. 29 cases, 60.4%), and @entity294 (4 cases, 7.3% vs. 5 cases, 10.4%) were observed and there were no significant differences(all P>0.05). It was noted that all these side effects vanished after chemotherapy or cured by symptomatic treatment. There were no significant differences between two groups in indexes of white blood cell, platelet, @entity3929 aminotransferase, @entity5906 transaminase, and @entity1011 (all P>0.05), neither after operation nor after chemotherapy. CONCLUSION: Peritoneal implantation of @entity13750 as intraoperative chemotherapy for advanced @entity14 is safe and tolerable.

[Safety evaluation of intraoperative peritoneal chemotherapy with @entity13750 for advanced XXXX ].

@entity1 :: ('9606', 'Species') :: ['patients'] @entity901 :: ('MESH:C030110', 'Chemical') :: ['Oxaliplatin'] @entity4181 :: ('MESH:D002955', 'Chemical') :: ['Leucovorin'] @entity390 :: ('MESH:D009325', 'Disease') :: ['nausea'] @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea'] @entity5906 :: ('D001224', 'Chemical') :: ['aspartate'] @entity281 :: ('MESH:D007239', 'Disease') :: ['infection'] @entity3929 :: ('D000409', 'Chemical') :: ['alanine'] @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal cancer'] @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine'] @entity1142 :: ('MESH:D003248', 'Disease') :: ['constipation'] @entity13750 :: ('MESH:C066228', 'Chemical') :: ['Lobaplatin'] @entity1487 :: ('MESH:D005472', 'Chemical') :: ['Fluorouracil']
@entity14 :: (MESH:D015179,Disease) :: ['colorectal cancers']
